Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baptist Gallwitz

Showing results (21-30 of 126) with videos related to

Pageof 13
Sort By:
Clinical Medicine Insights. Endocrinology and Diabetes|August 11, 2012
Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapyBaptist Gallwitz
MMW Fortschritte Der Medizin|August 3, 2010
[Modern diabetes management. DPP-4 inhibitors have been established as progress (interview by Christine Vetter)]Baptist Gallwitz
Expert Opinion on Drug Safety|September 22, 2017
A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetesBaptist Gallwitz
MMW Fortschritte Der Medizin|March 24, 2004
[A new long-acting insulin analog. "Fewer hypoglycemias observed"]Baptist Gallwitz
The Review of Diabetic Studies : RDS|January 1, 2010
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsBaptist Gallwitz
Treatments in Endocrinology|December 2, 2005
Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitusBaptist Gallwitz
Therapeutics and Clinical Risk Management|May 23, 2015
Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptinBaptist Gallwitz
European Endocrinology|April 11, 2018
GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015Baptist Gallwitz
Herz|May 15, 2010
[Incretins: do they exert cardiovascular effects?]Baptist Gallwitz
MMW Fortschritte Der Medizin|November 9, 2016
[Therapy with oral antidiabetic drugs]Baptist Gallwitz
Pageof 13

Showing results (21-30 of 126) with videos related to

Sort By:
Pageof 13
Clinical Medicine Insights. Endocrinology and Diabetes|August 11, 2012
Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapyBaptist Gallwitz
MMW Fortschritte Der Medizin|August 3, 2010
[Modern diabetes management. DPP-4 inhibitors have been established as progress (interview by Christine Vetter)]Baptist Gallwitz
Expert Opinion on Drug Safety|September 22, 2017
A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetesBaptist Gallwitz
MMW Fortschritte Der Medizin|March 24, 2004
[A new long-acting insulin analog. "Fewer hypoglycemias observed"]Baptist Gallwitz
The Review of Diabetic Studies : RDS|January 1, 2010
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsBaptist Gallwitz
Treatments in Endocrinology|December 2, 2005
Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitusBaptist Gallwitz
Therapeutics and Clinical Risk Management|May 23, 2015
Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptinBaptist Gallwitz
European Endocrinology|April 11, 2018
GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015Baptist Gallwitz
Herz|May 15, 2010
[Incretins: do they exert cardiovascular effects?]Baptist Gallwitz
MMW Fortschritte Der Medizin|November 9, 2016
[Therapy with oral antidiabetic drugs]Baptist Gallwitz
Pageof 13